Stock Market

Novartis to buy U.S.-based biotech firm Excellergy for up to $2 billion

By Bullbit Editorial · March 27, 2026

WhatNovartis agreed to acquire U.S.-based biotech firm Excellergy for up to $2 billion.
WhyThe acquisition aims to expand Novartis' presence in the biotech sector.
SignalThis move signals Novartis' growing interest in innovative biotech solutions.
TargetExcellergy's research on advanced biotechnology is the primary target of the acquisition.
RiskThe deal may pose risks to Novartis' financial stability, with a price tag of up to $2 billion.